Agios Pharmaceuticals (AGIO) Given Coverage Optimism Score of 0.37
News headlines about Agios Pharmaceuticals (NASDAQ:AGIO) have been trending positive recently, Accern Sentiment reports. Accern ranks the sentiment of news coverage by monitoring more than twenty million blog and news sources in real time. Accern ranks coverage of publicly-traded companies on a scale of -1 to 1, with scores nearest to one being the most favorable. Agios Pharmaceuticals earned a coverage optimism score of 0.37 on Accern’s scale. Accern also assigned news headlines about the biopharmaceutical company an impact score of 33 out of 100, indicating that recent news coverage is unlikely to have an impact on the company’s share price in the near term.
Here are some of the headlines that may have effected Accern’s rankings:
- Taking a Look Under the Hood at Agios Pharmaceuticals Inc (AGIO) Shares – Stock Press Daily (stockpressdaily.com)
- Agios Pharmaceuticals, Inc. (AGIO) Forecasted to Earn Q2 2017 Earnings of ($1.48) Per Share (americanbankingnews.com)
- Recent FDA Decisions and Clinical Trial Developments Influencing Current Biotech Run – Markets Insider (markets.businessinsider.com)
- Agios Pharmaceuticals, Inc. (AGIO) Insider Sells $1,379,501.60 in Stock (americanbankingnews.com)
- David P. Schenkein Sells 27,000 Shares of Agios Pharmaceuticals, Inc. (AGIO) Stock (americanbankingnews.com)
AGIO has been the topic of a number of research analyst reports. Zacks Investment Research lowered Agios Pharmaceuticals from a “hold” rating to a “sell” rating in a research note on Tuesday, April 18th. Credit Suisse Group restated an “outperform” rating and issued a $61.00 target price on shares of Agios Pharmaceuticals in a research note on Tuesday, April 18th. Cann restated a “buy” rating and issued a $75.00 target price on shares of Agios Pharmaceuticals in a research note on Wednesday, April 19th. Canaccord Genuity set a $90.00 target price on Agios Pharmaceuticals and gave the stock a “buy” rating in a research note on Thursday, May 4th. Finally, Oppenheimer Holdings, Inc. set a $75.00 target price on Agios Pharmaceuticals and gave the stock a “buy” rating in a research note on Thursday, June 1st. Five investment analysts have rated the stock with a hold rating and nine have issued a buy rating to the stock. The company presently has an average rating of “Buy” and an average target price of $67.25.
Agios Pharmaceuticals (NASDAQ:AGIO) traded down 2.51% during trading on Friday, hitting $61.46. The stock had a trading volume of 477,021 shares. The company has a 50-day moving average of $55.14 and a 200 day moving average of $50.99. Agios Pharmaceuticals has a 52-week low of $35.84 and a 52-week high of $67.74. The firm’s market cap is $2.96 billion.
Agios Pharmaceuticals (NASDAQ:AGIO) last issued its earnings results on Thursday, May 4th. The biopharmaceutical company reported ($1.56) earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of ($1.80) by $0.24. Agios Pharmaceuticals had a negative return on equity of 71.20% and a negative net margin of 491.54%. The firm had revenue of $10.51 million for the quarter, compared to analysts’ expectations of $9.65 million. During the same period in the previous year, the firm posted ($0.64) earnings per share. The business’s revenue was down 66.4% compared to the same quarter last year. On average, equities research analysts predict that Agios Pharmaceuticals will post ($6.43) earnings per share for the current fiscal year.
In other Agios Pharmaceuticals news, Director Lewis Clayton Jr. Cantley sold 2,036 shares of the business’s stock in a transaction that occurred on Thursday, May 25th. The stock was sold at an average price of $47.10, for a total transaction of $95,895.60. Following the sale, the director now directly owns 91,206 shares of the company’s stock, valued at $4,295,802.60. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, CEO David P. Schenkein sold 3,000 shares of the business’s stock in a transaction that occurred on Wednesday, June 7th. The stock was sold at an average price of $50.02, for a total value of $150,060.00. Following the sale, the chief executive officer now directly owns 1,100 shares in the company, valued at $55,022. The disclosure for this sale can be found here. Insiders sold 79,120 shares of company stock worth $4,557,207 over the last ninety days. Insiders own 10.55% of the company’s stock.
WARNING: “Agios Pharmaceuticals (AGIO) Given Coverage Optimism Score of 0.37” was published by The Cerbat Gem and is the sole property of of The Cerbat Gem. If you are reading this article on another publication, it was stolen and reposted in violation of United States & international copyright laws. The correct version of this article can be viewed at https://www.thecerbatgem.com/2017/08/04/positive-press-coverage-unlikely-to-impact-agios-pharmaceuticals-agio-share-price-updated-updated-updated.html.
About Agios Pharmaceuticals
Agios Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company. The Company’s therapeutic areas of focus are cancer and rare genetic metabolic disorders, which are a group of over 600 rare genetic diseases caused by mutations, or defects, of single metabolic genes. The Company’s cancer product candidates are enasidenib and ivosidenib (AG-120), which target mutated isocitrate dehydrogenase 2 (IDH2) and isocitrate dehydrogenase 1 (IDH1), respectively, and AG-881, which targets both mutated IDH1 and mutated IDH2.
Receive News & Stock Ratings for Agios Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Agios Pharmaceuticals Inc. and related stocks with our FREE daily email newsletter.